Editorially independent content, supported with advertising
08.21.25
Time flies: Some wet AMD patients have had the Port Delivery System with Ranibizumab (Susvimo, Genentech/Roche) for more than 5 years. How well does vision hold up at 5 years? And how do those numbers compare to 5-year endpoints in injection-based studies? John Kitchens, MD, reviews the dynamics around the PORTAL study, which assessed outcomes after 5 years of PDS treatment. And Krishna Mukkamala, MD, reviews data from a first-ever study validating longitudinal performance of AI-based home OCT (Scanly Home OCT, Notal Vision) compared with human experts. Just how sensitive and specific was home OCT compared with human graders?
Editorially independent content, supported by Genentech
09.04.25
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDRDavid Lally, MD; and Ehsan Rahimy, MD
Editorially independent content, supported by Genentech
08.21.25
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human GradersJohn Kitchens, MD; Krishna Mukkamala, MD
Editorially independent content, supported by Genentech
06.12.25
Duke AVS Clips: PVR, DR, Imaging, and MTMJason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed
Editorially independent content
06.09.25
Duke AVS Clips: Pediatrics, Anesthesia Trends, and AILejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD
Editorially independent content
06.05.25
Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDsAvni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD
Editorially independent content
05.29.25
ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation DataMarion Munk, MD, PhD; and Diana Do, MD
Editorially independent content, supported by Genentech
05.22.25
ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the PipelineDavid Miller, MD; and Robert Wang, MD
Editorially independent content, supported by Genentech
12.05.24
AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer'sAdrienne Scott, MD; and Dilraj Grewal, MD
Editorially independent content supported by Genentech.
11.14.24
AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GADurga S. Borkar, MD, MMCi; and Alex Melamud, MD
Editorially independent content supported by Genentech.
11.07.24
AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMDJeremiah Brown, MD, MS; and Eric Schneider, MD
Editorially independent content supported by Genentech.
Show More